RNA polymerase (pol) III synthesizes a range of essential products, including tRNA, 5S rRNA and 7SL RNA, which are required for protein synthesis and trafficking. High rates of pol III transcription are necessary for cells to sustain growth. A wide range of transformed and tumour cell types have been shown to express elevated levels of pol III products. This review will summarize what is known about the mechanisms responsible for this deregulation. Some transforming agents have been shown to stimulate expression of the pol III-specific transcription factors TFIIIB or TFIIIC2. In addition, TFIIIB is bound and activated by several oncogenic proteins, including cMyc. Conversely, TFIIIB interacts in healthy cells with the tumour suppressors RB and p53. Indeed, the ability to limit pol III transcription through TFIIIB may contribute to their growth-suppression capacities. The function of p53 and/or RB is compromised in most if not all transformed cells; the resultant derepression of TFIIIB may provide an almost universal route to deregulate pol III transcription in cancers. In addition to effects on protein synthesis and growth, there is a precedent for a pol III product having oncogenic activity.
Introduction
Every ribosome contains one copy each of the four rRNAs. The largest three of these are made by RNA polymerase (pol) I, as a single precursor transcript that is processed into the final mature products. In contrast, the 5S rRNA is synthesized independently by pol III, a unique RNA polymerase with a distinct set of transcription factors. Because of this curious anomaly, ribosome biosynthesis is just as dependent on pol III as it is on pol I, although the latter is devoted exclusively to this purpose. An additional source of dependence is provided by the pol III product MRP RNA, which is required for processing the pol I transcript into mature rRNAs. Any consideration of ribosome biogenesis is therefore incomplete unless pol III is taken into account.
Pol III is the largest RNA polymerase with the greatest number of subunits (Schramm and Hernandez, 2002; White, 2002) . All of its products are short untranslated transcripts, which rarely exceed 300 nucleotides in length. Apart from 5S rRNA and MRP RNA, they include tRNA, which is required for translation, and the 7SL RNA, which is needed to introduce proteins into membranes as part of the signal recognition particle. Other essential pol III products include the U6 and H1 RNAs, which are involved in processing mRNA and tRNA, respectively (White, 2002) . Pol III transcription occurs at unique sites within the nucleoplasm, each of which contains five molecules of active polymerase on average (Pombo et al., 1999) . Around two thousand of such sites are found in a HeLa cell (Pombo et al., 1999) .
Since the output of pol I is concerned exclusively with protein synthesis and much of the output of pol III is required for the same end, one might predict that these two systems would be regulated coordinately; this may be especially important for the 5S rRNA, which is required in equimolar quantities with the other rRNA molecules. In general, this coregulation seems to be the case (reviewed by White, 2004) . For example, the activities of mammalian pols I and III increase in parallel following serum stimulation and fluctuate together during passage through the cell cycle (Johnson et al., 1974; Mauck and Green, 1974; White et al., 1995; Klein and Grummt, 1999) . Such coordination may be of considerable importance to the balance of cellular metabolism, given the amount of energy expended in generating rRNA and tRNA. Indeed, complex mechanisms exist to ensure that the outputs of pols I and III are matched to a cell's biosynthetic requirements. However, transformed cells subvert these controls and can synthesize rRNA and tRNA at highly elevated rates.
Abnormal pol III activity is a feature of cancer cells
Early evidence for such deregulation came from the finding that pols I and III are both hyperactive in mice with myelomas, whereas the overall activity of pol II remains normal (Schwartz et al., 1974) . However, it had been known for over a century that nucleolar hypertrophy is a consistent cytological feature of cancer cells (Pianese, 1896) . Indeed, enlarged nucleoli are used by pathologists as a strong diagnostic indicator of cell transformation (Busch and Smetana, 1970; Derenzini and Ploton, 1994; King, 1996) . This indicates that transformation in situ is tightly linked to the deregulation of pols I and III, because the size of the nucleolus reflects the level of rRNA synthesis (Kurata et al., 1978; Altmann and Leblond, 1982; Moss and Stefanovsky, 1995) . A wide variety of transformed cell types have been shown to overexpress the products of pols I and III, including lines transformed by DNA tumour viruses (e.g. hepatitis B virus), RNA tumour viruses (e.g. human T-cell leukaemia virus 1) and chemical carcinogens (Liebhaber et al., 1978; Scott et al., 1983; White et al., 1990; Wang et al., 1995 Wang et al., , 1997 Gottesfeld et al., 1996; Ying et al., 1996; Larminie et al., 1999; Zhai and Comai, 1999; Felton-Edkins and White, 2002) . Although most of these studies have employed cell lines, their relevance has been validated for tumours in situ (Chen et al., 1997a, b; Winter et al., 2000) . For example, RT-PCR showed that rRNA and tRNA are overproduced consistently in human ovarian cancers . An extensive Northern analysis of 80 tumour specimens representing 19 types of cancer revealed that 7SL RNA is abnormally abundant in every tumour analysed, relative to healthy tissue from the same patients (Chen et al., 1997a) . Furthermore, in situ hybridization of breast, lung and tongue carcinomas revealed increased levels of pol III transcripts in neoplastic cells relative to the surrounding healthy tissue (Chen et al., 1997a, b) .
Overexpression of pol III transcription factors in transformed cells
Considerable progress has been made in elucidating the molecular mechanisms that are responsible for raising pol III output in transformed cells. They can be broadly classified into three groups: (1) overexpression of pol III transcription factors; (2) release from repressors that control output in healthy cells; and (3) direct activation by oncogene products that are deregulated during cell transformation (Figure 1) .
The most obvious way to increase pol III output is by raising the level of one or more of the limiting transcription factors on which it depends. The first evidence for such behaviour came from studies of DNA tumour viruses, which revealed that adenoviral infection or SV40 transformation can raise the activity of the pol III-specific factor TFIIIC2 (Hoeffler and Roeder, 1985; Yoshinaga et al., 1986; Hoeffler et al., 1988; White et al., 1990) . TFIIIC2 is a large DNA-binding protein composed of five subunits, that recognizes promoter sequences directly and nucleates transcription complex assembly on most pol III templates (Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; White, 2002) . Subsequent studies revealed that all five Figure 1 Model to illustrate the mechanisms contributing to increased pol III transcription in tumours. In untransformed cells, TFIIIB is subject to repression by RB and p53; these constraints are often removed in transformed cells. In contrast, the interaction of TFIIIB with oncogenic proteins such as Erk and c-Myc may increase following transformation. Some transformed cells also overexpress components of the pol III machinery, such as TFIIIC2 of its subunits are overexpressed at both the mRNA and protein levels in fibroblasts transformed by SV40 or polyomavirus (Felton-Edkins and White, 2002; Larminie et al., 1999) . This discovery proved to be of clinical significance when elevated TFIIIC2 activity was found in each of nine human ovarian carcinomas relative to healthy adjacent tissue . Again, this reflected a specific increase in the levels of mRNAs encoding all five subunits . The mechanisms responsible for raising TFIIIC2 expression have yet to be determined, but they do not seem to reflect a simple response to accelerated proliferation Scott et al., 2001) .
Transformation
Once TFIIIC2 is bound to DNA, it serves to recruit the essential factor TFIIIB to the promoter; TFIIIB is then responsible for positioning the polymerase at the transcription start site (Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; White, 2002) . TFIIIB is composed of three subunits, TBP, Bdp1 (formerly B 00 ) and Brf1, each of which has been shown to be elevated in particular types of transformed cell. This was first shown for TBP, which can be induced in culture by hepatitis B virus and Ras activation Johnson et al., 2000) . Accordingly, elevated TBP levels are sometimes found in colon tumours, where Ras mutations are common . An increase in TBP is likely to impact on a wide range of genes, since all three nuclear RNA polymerases make use of this factor (Hernandez, 1993) . However, the pol III-specific subunits of TFIIIB are also overproduced in some transformed cells. A screen of seven cervical carcinomas revealed one that expressed very high levels of Bdp1 mRNA (Daly et al., submitted for publication). Although this event was sufficiently rare that it might have arisen by chance, elevated Bdp1 expression was also found consistently in cell lines transformed by SV40 or polyomavirus (Felton-Edkins and White, 2002) . Brf1 levels were normal in the above cases, but were found to correlate with infection by human papillomavirus 16 (HPV16), the most prevalent cause of cervical cancer (zur Hausen, 2000 (zur Hausen, , 2002 . Thus, Brf1 mRNA was clearly elevated in cervical biopsies that tested positive for the highly oncogenic HPV16 strain, relative to biopsies that were HPV-negative or infected with lower risk HPV strains (Daly et al., submitted for publication).
Derepression of TFIIIB
Although several examples have now been reported in which pol III factor levels are raised in particular transformed cell types, these instances seem less widespread than the increase in pol III transcripts, which is found with few exceptions. A far more universal route to deregulate pol III transcription was suggested by the discovery that this system can be strongly repressed by the retinoblastoma tumour suppressor RB (White et al., 1996) . Several groups have shown independently that overexpressing RB can potently inhibit pol III transcription in transfected cells or in vitro (White et al., 1996; Chu et al., 1997; Larminie et al., 1997; Hirsch et al., 2000) . This is due to the binding of RB to TFIIIB, which blocks its interactions with TFIIIC2 and pol III (Larminie et al., 1997; Sutcliffe et al., 2000) . Inactivation of RB will therefore derepress TFIIIB and allow increased rates of pol III transcription. This was demonstrated clearly with fibroblasts from RB-knockout mice, which show substantially elevated synthesis of tRNA and 5S rRNA when compared to matched wild-type cells (White et al., 1996; Scott et al., 2001) . RB is expressed ubiquitously in mammals, and it is believed that RB function must be compromised for a cancer to develop (Weinberg, 1995) . This often occurs through mutation of the RB gene, as is found in retinoblastomas (DiCiommo et al., 2000) . In all, 98% of such mutations involve the large pocket domain of RB, which spans residues 393-928 (Harbour, 1998) . This region is necessary and sufficient for RB to bind TFIIIB and repress pol III transcription (White et al., 1996; Chu et al., 1997; Larminie et al., 1997) . Accordingly, this function is ablated by substitutions or small deletions in the pocket that arose naturally in tumours (White et al., 1996; Brown et al., 2000; Felton-Edkins et al., 2003b) . (Figure 2 ). Several DNA tumour viruses encode oncoproteins that neutralize RB by binding to its pocket (Vousden, 1995) . These include the E1A product of adenovirus, the E7 product of HPV and the large T antigens of SV40 and polyomavirus, all of which have been shown to release TFIIIB from repression and thereby stimulate pol III transcription in vitro and in vivo (White et al., 1996; Larminie et al., 1999; Sutcliffe et al., 1999; Felton-Edkins and White, 2002) . Substitutions in E7 that preclude its interaction with RB also block its effect on a pol III reporter (Larminie et al., 1999; Sutcliffe et al., 1999) . Probably the most prevalent mechanism by which RB function is compromised in tumours is through its deregulated hyperphosphorylation by cyclin D-and E-dependent kinases (Hunter and Pines, 1994; Bates and Peters, 1995; Sherr, 2001 ). These kinases have been shown to stimulate pol III transcription, because hyperphosphorylated RB fails to bind to TFIIIB in vitro or in vivo . Whereas many tumours overexpress cyclin D or cdk4, others deregulate the cyclin D-dependent kinases by mutating or silencing INK4a, a tumour suppressor gene that encodes the p16 inhibitor of cdk4 and cdk6 (Hirama and Koeffler, 1995; Rocco and Sidransky, 2001; Sherr, 2001) . To mimic this occurrence, a specific ribozyme was used to deplete cells of endogenous p16, with the result that pol III transcription increased . It has therefore been confirmed that derepression of TFIIIB can result from each of the mechanisms that undermine RB control in tumours -mutation, hyperphosphorylation or sequestration by viral oncoproteins. Since one or another of these routes is believed to compromise RB function in most if not all cancers, release from repression may provide a universal mechanism to deregulate pol III transcription in transformed cells.
TFIIIB is bound and repressed not only by RB but also by p53 (Chesnokov et al., 1996; Cairns and White, 1998; Crighton et al., 2003) . When bound by p53, TFIIIB is unable to interact with TFIIIC2 or be recruited to pol III templates (Crighton et al., 2003) . Consequently, p53 induction results in a marked decrease in the amounts of TFIIIB and pol III present at chromosomal tRNA genes (Crighton et al., 2003) (Figure 3) . Conversely, promoter occupancy is elevated substantially in p53-knockout mice, in keeping with a marked increase in tRNA and 5S rRNA synthesis (Cairns and White, 1998; Crighton et al., 2003) . This suggests that increased pol III output will result from the ablation of p53 in tumours. The cellular oncoprotein hdm2 and the HPV oncoprotein E6 both target wildtype p53 for degradation and, accordingly, can derepress a pol III reporter in transfected cells (Stein et al., 2002a) . Mutant forms of p53 are expressed in around half of all human malignancies and 75% of these carry missense substitutions, usually in the central core domain (Hollstein et al., 1994; Bullock et al., 2000) . This region is required for p53 to regulate TFIIIB and, indeed, repression was compromised largely or completely in three of the four tumour-derived substitution mutants tested (Stein et al., 2002a, b) . Pol III transcriptional activity is also frequently elevated in primary human fibroblasts carrying inherited mutations in p53 (Stein et al., 2002b) . The available data therefore argue that loss or mutation of p53 will contribute to the derepression of TFIIIB in a significant fraction of human malignancies.
Direct activation of TFIIIB
In addition to being inhibited by RB and p53, TFIIIB is also a direct target for several oncogenic proteins that stimulate its activity. This was first demonstrated for the Tax oncoprotein of HTLV-1, which has been shown to stimulate pol III transcription in vitro and may therefore have a similar effect in adult T-cell leukaemias (Gottesfeld et al., 1996) . The proto-oncogene product c-Myc interacts with TFIIIB and has a potent stimulatory effect on transcription by pol III in mouse and human cells (Gomez-Roman et al., 2003) . Chromatin immunoprecipitation revealed the presence of endogenous c-Myc at chromosomal tRNA, 5S rRNA and B2 genes of both transformed and untransformed cells (Felton-Edkins et al., 2003b; Gomez-Roman et al., 2003) . Expression of these genes is markedly compromised in c-Myc-knockout fibroblasts or in HeLa cells depleted by RNA interference (Felton-Edkins et al., 2003b; Gomez-Roman et al., 2003) . The available evidence suggests that c-Myc makes a significant contribution to the level of pol III output in normal cycling mammalian cells. One can infer that pol III transcription may be further stimulated in the many malignancies that overexpress this important factor. These include Burkitt's lymphomas and carcinomas of the breast and colon (Nesbit et al., 1999) .
Two oncogenic kinases have also been found to bind TFIIIB and activate pol III transcription. CK2 is ubiquitous and highly conserved through evolution (Litchfield and Luscher, 1993; Allende and Allende, 1995). It binds and phosphorylates TFIIIB in both yeast and mammals, and can increase pol III transcription dramatically by facilitating assembly of the initiation complex (Hockman and Schultz, 1996; Schultz, 1997, 2001; Johnston et al., 2002) . It induces lymphomas in transgenic mice and is hyperactive in some human malignancies (Faust et al., 1996; Munstermann et al., 1990; Notterman et al., 2001; Seldin and Leder, 1995) . Elevated pol III output may be driven by CK2 in such circumstances, although this has yet to be tested experimentally. The MAP kinase Erk has also been shown to stimulate the assembly of pol III transcription complexes in mammals (Felton-Edkins et al., 2003a) . This involves its direct binding to the Brf1 subunit of TFIIIB, which is phosphorylated as a consequence (Felton-Edkins et al., 2003a) . Pol III transcription can be compromised by substitutions in the Erk docking or phosphoacceptor sites of Brf1 (Felton-Edkins et al., 2003a) . Erk is activated in response to mitogens through a signaling cascade involving Ras and Raf (Downward, 2002) . Activating mutations in either of these oncoproteins will stimulate expression of a pol III reporter in transfected fibroblasts (Felton-Edkins et al., 2003a) . Mutagenic activation of Ras is found in around 20% of all human tumours (Downward, 2002) . As a consequence of these and other aberrations, including mutations in Raf, the Erk kinases are hyperactive in B30% of cancers (Downward, 2002 ). This may result in constitutive TFIIIB phosphorylation and further deregulation of the pol III system.
Coordinate regulation of pols I and III
The above description of how pol III can be deregulated in tumours is strongly reminiscent of the pol I system (for a detailed comparison, see White, 2004) . For example, the pol I transcription factor UBF was found to be overexpressed in 11 out of 16 hepatocellular carcinomas and less frequently in breast and ovarian carcinomas (Huang et al., 2002) . Hepatitis B virus can stimulate pol I transcription by raising TBP levels in a Ras-dependent manner . A more immediate effect of Ras can be mediated through Erk, which can bind, phosphorylate and activate two components of the pol I machinery (Stefanovsky et al., 2001; Zhao et al., 2003) . Synthesis of large rRNA is also stimulated by CK2, which binds and phosphorylates both UBF and pol I itself (Belenguer et al., 1989; Voit et al., 1992 Voit et al., , 1995 Hannan et al., 1998; Voit and Grummt, 2001 ). In addition, rRNA levels are reduced in c-Myc knockout fibroblasts (Mateyak et al., 1997) and are raised by overexpression of N-Myc (Boon et al., 2001) . We have evidence to indicate that this effect is direct (C Grandori, ZA Felton-Edkins, N GomezRoman, RN Eisenman and RJW, unpublished observa- Figure 3 Model illustrating how the binding of p53 to TFIIIB can prevent assembly of a pol III transcription complex. When bound by p53, TFIIIB cannot interact efficiently with TFIIIC2 or pol III and is not recruited to pol III-transcribed genes (Crighton et al., 2003) . Once assembled, the pol III transcription complex is relatively resistant to challenge by p53 (Cairns and White, 1998) . Note: p53 does not interact with assembled TFIIIB and so is not detected at the pol III promoters it regulates (Crighton et al., 2003) tions). The pol I machinery is also targeted by RB and p53, both of which can reduce its output (Cavanaugh et al., 1995; Voit et al., 1997; Hannan et al., 2000a,b; Pelletier et al., 2000; Zhai and Comai, 2000; Ciarmatori et al., 2001; Sugimoto et al., 2003) . It therefore appears that pols I and III are both enmeshed in a network of regulatory interactions that help to coordinate their outputs and promote balanced production of ribosomal components.
Pols I and III may help mediate the growth control functions of tumour suppressors
The importance of controlling pols I and III is suggested strongly by the range of key regulators that target these systems directly and the frequency with which they become deregulated in cancers. Several authors have suggested that restraining rRNA and tRNA synthesis may be an important component of the growth control function of RB (Nasmyth, 1996; White, 1997; Ruggero and Pandolfi, 2003) . A common misconception is that the activity of RB can be simply explained by its ability to repress E2F. However, although E2F can induce limited cell cycle progression, it does not promote the cell growth (increase in mass) that is essential for sustained proliferation Beier et al., 2000) . Alternative interactions must therefore explain the ability of RB to restrain growth. In support of this, the RB mutant 661W retains the ability to arrest cell growth, despite being unable to bind E2F (Kratzke et al., 1994; Sellers et al., 1998; Whitaker et al., 1998) . It is noteworthy that the 661W mutant remains capable of repressing pol III transcription (Felton-Edkins et al., 2003b) . RB is estimated to be two orders of magnitude more abundant than E2F and can bind and regulate a great variety of targets (Weinberg, 1995; Grana et al., 1998; Mulligan and Jacks, 1998) . The relative contributions of its many targets have yet to be elucidated. Nevertheless, its capacity to repress pols I and III provides a clear link to growth control. A similar argument can be made for p53, which inhibits growth under a range of stress conditions, including hypoxia, ribonucleotide depletion and DNA damage (Oren, 1999) . Under such circumstances, restricting biosynthesis may be important to maintain cell viability. Reducing the production of rRNA and tRNA might be especially advantageous when ribonucleotide pools are depleted, since these transcripts comprise B95% of a cell's RNA content (Warner, 1999) . Indeed, we find that such conditions do trigger a p53-dependent repression of pol III transcription (JP Morton and RJW, unpublished observations). In addition, the tumour suppressor Arf has a p53-independent capacity to inhibit rRNA production, operating at the post-transcriptional level (Sugimoto et al., 2003) . Sherr has argued that this may constitute its original function, serving to slow ribosome biogenesis under conditions of stress; evolution may then have linked Arf to the Mdm2/ p53 pathway, thereby coordinating ribosome synthesis with cell cycle progression (Sugimoto et al., 2003) .
At present, there is no direct evidence that tumour suppressors do in fact use the repression of pols I and III as a means to achieve growth restraint. However, it is unquestionable that growth and proliferation can be prevented when the production of rRNA or tRNA becomes limiting. The crucial issue is to what extent this ever happens under physiological circumstances. Striking experiments using mutants of the pol I-specific factor TIF-IA suggest that rRNA synthesis is indeed limiting in HEK293 T cells. Thus, a constitutively active TIF-IA mutant accelerated proliferation by 43%, whereas dominant negative TIF-IA produced a 33% slowing (Zhao et al., 2003) . Similarly, the hypertrophic growth of rat cardiac myocytes can be blocked by specifically preventing a 37% increase in rRNA synthesis (Brandenburger et al., 2001) . The magnitude of these changes compares closely with the B40% suppression of rRNA synthesis exerted by endogenous RB and its relative p130 in embryonic fibroblasts, as determined with knockout mice (Ciarmatori et al., 2001) . A similar genetic analysis found that endogenous RB suppresses tRNA levels by 2.4-fold in serum-starved mouse embryonic fibroblasts . It remains to be determined whether this is sufficient to restrict the growth of mammalian cells, but an B2-fold reduction in the level of a tRNA slows the doubling time of yeast by B3-fold (Francis and Rajbhandary, 1990) . Such quantitative comparisons make it seem likely that growth rates can indeed be limited through the repression of pols I and III by RB and its relatives. This might only be the case under particular conditions, whereas other pathways may mediate growth restraint in different cell types or circumstances. Nevertheless, the possibility of restricting growth through pol I and/or pol III may serve a crucial regulatory function in some situations. Loss of such controls during tumour development may be an important step towards neoplastic growth.
Transformation by pol III transcripts?
Apart from its impact on protein synthesis, activating pol III transcription might also have phenotypic effects that are independent of the translation apparatus, since pol III products have a wide range of functions (White, 2002) . Particularly intriguing in this regard are the EBER RNAs of Epstein-Barr virus (EBV), which are expressed at very high levels in EBV-transformed lymphocytes (Arrand and Rymo, 1982) . Although EBER RNA is only B170 nt long and encodes no protein, it has been shown by several groups to be sufficient to induce growth in soft agar and tumorigenicity in mice (Laing et al., 1995; Komano et al., 1999; Kitagawa et al., 2000; Ruf et al., 2000; Yamamoto et al., 2000) . Clones with the highest EBER expression are the most tumorigenic (Ruf et al., 2000) . This provides the first example of an oncogenic RNA and a proof of principle that a pol III product can have transforming potential under certain circumstances. The mechanism of action has yet to be fully characterized. There is a specific increase in IL-10 expression following EBER transfection, providing an autocrine loop that allows Burkitt lymphoma cells to grow in low serum (Kitagawa et al., 2000) . EBERs also protect cells against the antiviral effects of interferon-a (Komano et al., 1999; Nanbo et al., 2002) . Indeed, EBV loses its ability to resist interferon if the EBER genes are deleted from its genome (Nanbo et al., 2002) . Conversely, transfection of EBER genes alone is sufficient to confer interferon resistance on EBV-negative Burkitt lymphoma lines (Nanbo et al., 2002) . This reflects the ability of EBER RNA to bind and inhibit the double-stranded RNAactivated protein kinase (PKR), a key mediator of the interferon response (Nanbo et al., 2002) . PKR phosphorylates translation initiation factor eIF2-a in order to inhibit protein synthesis (Akusjarvi et al., 1987; Davies et al., 1989; Thimmappaya et al., 1982) . This can be prevented by EBERs, which bind PKR tightly and block its function (Clarke et al., 1991; Elia et al., 1996; Nanbo et al., 2002; Sharp et al., 1993) . Since PKR has been shown to exert tumour suppressor activity in model systems (Clemens, 1992; Koromilas et al., 1992; Lengyel, 1993; Meurs et al., 1993) , its neutralization by EBERs can account, at least in part, for their oncogenic effects. The EBER genes establish a very important precedent for the possibility that a pol III product can transform cells. If a viral RNA can do this, it is feasible that one or more cellular pol III transcripts could also have transforming properties if aberrantly expressed.
Conclusions
In untransformed cells, pol III transcription is subject to powerful restraints by RB and p53, both of which act on TFIIIB. Since active pol III transcription is required for cell growth and proliferation, the ability of these tumour suppressors to inhibit TFIIIB may contribute to their growth control functions. These restraints are likely to be compromised in the overwhelming majority of tumours, where the p53 and/or RB pathways are undermined. A priori, this might seem sufficient to allow the high rates of pol III transcription that are a prerequisite of rapid growth. This is certainly the case in embryonic fibroblasts from RB-or p53-knockout mice (Cairns and White, 1998; White et al., 1996) . Nevertheless, oncogene products such as c-Myc and Erk bind and activate TFIIIB, and may further increase pol III output in many transformed cell types.
Since RB, p53, Erk and Myc all regulate multiple targets, it is difficult to know which interactions are of greatest significance for cancer development. Indeed, a sceptic might argue that deregulation of pol III is an irrelevant side-effect of the changes to oncogenes and tumour suppressors. For example, a tumour might select for mutation of RB simply to activate E2F, remaining indifferent to the impact on TFIIIB. This raises an obvious question, which is why mutational activation of E2F is such a rare event in cancers? It is much more likely that RB or its upstream regulators are targeted preferentially to allow multiple downstream targets to be deregulated through a single mutagenic event. The relative importance of these targets will be difficult to unravel and may depend upon circumstances.
Direct evidence that pol III activation per se is of value to a tumour came from the finding that TFIIIC2 is overexpressed consistently in ovarian carcinomas. Although the study was small (only nine patients were tested), each tumour examined displayed elevated TFIIIC2 activity . Furthermore, mRNAs encoding all five subunits of TFIIIC2 were upregulated . This provides a strong indication that there is direct selection for increased pol III output in this context, since TFIIIC2 is a dedicated pol III-specific factor, with no other known function. There is therefore good reason to believe in the relevance of pol III transcription for the complex process of tumour development. Progress has been made towards determining how the system becomes activated during transformation, although there are many unanswered questions. To my mind though, the most burning issues concern the consequences of raising pol III activity. What effects does this have on a cell? The EBER precedent of EBV has unexpectedly indicated that high levels of a pol III transcript can have oncogenic consequences. Could this be true of other pol III products? After all, many oncogenes were discovered in viruses and subsequently found to have cellular counterparts. At the very least, we can be confident that pol III activity will help determine the growth potential of cells. As such, it might offer a useful target for therapeutic intervention.
